[en] Background: Eculizumab, a terminal complement inhibitor, is approved for atypical haemolytic uraemic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). Methods: In five parent studies, eculizumab effectively prevented TMA and improved renal and haematologic outcomes in patients with aHUS; therefore, these patients could enrol in this long-term, prospective, observational and multicentre study. The primary endpoint was the TMA manifestation rate off and on eculizumab post-parent study. Post hoc analyses evaluated rates during labelled versus non-labelled dosing regimens, and in those with versus without identified complement abnormalities. Serious targeted treatment-emergent adverse events (TEAEs) were evaluated. Results: Of 87 patients in the current study, 39 and 76 had off- and on-treatment periods, respectively; 17 (44%) with off periods reinitiated eculizumab. TMA manifestation rate per 100 patient-years was 19.9 off and 7.3 on treatment [hazard ratio (HR), 4.7; P = 0.0008]; rates were highest off treatment and lowest during labelled regimens. TMA manifestations with hospitalizations/serious AEs occurred more frequently off versus on treatment. TMA rates were higher among patients with identified complement abnormalities (HR, 4.5; P = 0.0082). Serious targeted TEAEs occurred at similar rates off and on treatment. Conclusions: As expected, patients with aHUS have increased risk of TMA manifestations after discontinuation of eculizumab or in the setting of non-labelled eculizumab dosing. Collectively, results show that maintaining eculizumab treatment minimizes risk of TMA, particularly in patients with identified complement abnormalities. Future studies are needed to further characterize TMA and longer term outcomes on labelled or non-labelled eculizumab regimens and after discontinuation of treatment.
Disciplines :
Urology & nephrology
Author, co-author :
Menne, Jan
Delmas, Yahsou
Fakhouri, Fadi
Kincaid, John F.
Licht, Christoph
Minetti, Enrico E.
Mix, Chris
Provot, Francois
Rondeau, Eric
Sheerin, Neil S.
Wang, Jimmy
WEEKERS, Laurent ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de néphrologie
Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-1687
Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5: 1844-1859
Fremeaux-Bacchi V, Fakhouri F, Garnier A et al. Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013; 8: 554-562
Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8: 622-633
US Food and Drug Administration. Soliris (eculizumab) [Prescribing Information]. New Haven, CT: Alexion Pharmaceuticals, Inc., 2017
European Medicines Agency. Soliris (eculizumab) [Summary of Product Characteristics]. Paris, France: Alexion Europe SAS, 2017
Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368: 2169-2181
Licht C, Greenbaum LA, Muus P et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 2015; 87: 1061-1073
Greenbaum LA, Fila M, Ardissino G et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 2016; 89: 701-711
Fakhouri F, Hourmant M, Campistol JM et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: A single-arm, open-label trial. Am J Kidney Dis 2016; 68: 84-93
Vilalta R, Al-Akash S, Davin J et al. Eculizumab therapy for pediatric patients with atypical hemolytic uremic syndrome: Efficacy and safety outcomes of a retrospective study [abstract 1155]. Haematologica 2012; 97 (Suppl 1): 479
Chatelet V, Fremeaux-Bacchi V, Lobbedez T et al. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009; 9: 2644-2645
Alachkar N, Bagnasco SM, Montgomery RA. Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft. Transpl Int 2012; 25: E93-e95
Cayci FS, Cakar N, Hancer VS et al. Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation. Pediatr Nephrol 2012; 27: 2327-2331
Carr R, Cataland SR. Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation. Ann Hematol 2013; 92: 845-846
Gulleroglu K, Fidan K, Hancer VS et al. Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol 2013; 28: 827-830
Pu JJ, Sido A. Successful discontinuation of eculizumab therapy in a patient with aHUS. Ann Hematol 2014; 93: 1423-1425
Coppo R, Peruzzi L, Amore A et al. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol 2015; 30: 167-172
Habbig S, Bergmann C, Weber LT. Discontinuation of eculizumab in a patient with atypical hemolytic uremic syndrome due to amutation in CFH. AmJ Kidney Dis 2016; 67: 532-533
Hayes W, Tschumi S, Ling SC et al. Eculizumab hepatotoxicity in pediatric aHUS. Pediatr Nephrol 2015; 30: 775-781
Java A, Edwards A, Rossi A et al. Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: Case report and review of the literature. Transpl Int 2015; 28: 1121-1125
Canigral C, Moscardo F, Castro C et al. Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome. Ann Hematol 2014; 93: 1421-1422
De Sousa Amorim E, Blasco M, Quintana L et al. Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: Insights for optimizing management. J Nephrol 2015; 28: 641-645
Wetzels JF, van De Kar NC. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome. Am J Kidney Dis 2015; 65: 342
Toyoda H, Wada H, Miyata T et al. Disease recurrence after early discontinuation of eculizumab in a patient with atypical hemolytic uremic syndrome with complement C3 I1157T mutation. J Pediatr Hematol Oncol 2016; 38: E137-e139
Sheerin NS, Kavanagh D, Goodship TH et al. A national specialized service in England for atypical haemolytic uraemic syndrome-The first year's experience. QJM 2016; 109: 27-33
Fakhouri F, Fila M, Provot F et al. Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin J Am Soc Nephrol 2017; 12: 50-59
Ardissino G, Testa S, Possenti I et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: A report of 10 cases. Am J Kidney Dis 2014; 64: 633-637
Ardissino G, Possenti I, Tel F et al. Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: An update. Am J Kidney Dis 2015; 66: 172-173
MaciaM, De AlvaroMoreno F, Dutt T et al. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J 2017; 10: 310-319
Vande Walle J, Delmas Y, Ardissino G et al. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol 2017; 30: 127-134
Loirat C, Fakhouri F, Ariceta G et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2016; 31: 15-39
Drug Safety and Risk Management Advisory Committee. Briefing Document for SolirisVR (eculizumab). Cheshire, CT: Alexion Pharmaceuticals, Inc., 2014
Licht C, Ardissino G, Ariceta G et al. The global aHUS registry: Methodology and initial patient characteristics. BMC Nephrol 2015; 16: 207
